Evidence map›Paper›PMID 37923795›Full record

ArticleScientific reports2023

Early and fair COVID-19 outcome risk assessment using robust feature selection.

Felipe O Giuste, Lawrence He, Peter Lais, Wenqi Shi, Yuanda Zhu, Andrew Hornback, Chiche Tsai, Monica Isgut, Blake Anderson, May D Wang

Abstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Diagnostic accuracy of image-based deep learning for glaucomatous optic neuropathy detection: a systematic review and meta-analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Felipe O GiusteThe Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30322, USA.ORCID 0000-0002-8355-3705
Lawrence HeThe Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30322, USA.
Peter LaisThe Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30322, USA.
Wenqi ShiSchool of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, 30322, USA.
Yuanda ZhuSchool of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, 30322, USA.
Andrew HornbackSchool of Computer Science and Engineering, Georgia Institute of Technology, Atlanta, GA, 30322, USA.
Chiche TsaiThe Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30322, USA.
Monica IsgutSchool of Biology, Georgia Institute of Technology, Atlanta, GA, 30322, USA.
Blake AndersonDepartment of Medicine, Emory University, Atlanta, GA, 30322, USA.
May D WangThe Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30322, USA. maywang@gatech.edu.

Funding

Medical Scientist Training ProgramT32GM142617 · NIGMS · EMORY UNIVERSITY · PI Jason Yustein · 2022 to 2026
$7.0M
NIGMS NIH HHS T32 GM142617
6 · The paper itself

Abstract

Personalized medicine plays an important role in treatment optimization for COVID-19 patient management. Early treatment in patients at high risk of severe complications is vital to prevent death and ventilator use. Predicting COVID-19 clinical outcomes using machine learning may provide a fast and data-driven solution for optimizing patient care by estimating the need for early treatment. In addition, it is essential to accurately predict risk across demographic groups, particularly those underrepresented in existing models. Unfortunately, there is a lack of studies demonstrating the equitable performance of machine learning models across patient demographics. To overcome this existing limitation, we generate a robust machine learning model to predict patient-specific risk of death or ventilator use in COVID-19 positive patients using features available at the time of diagnosis. We establish the value of our solution across patient demographics, including gender and race. In addition, we improve clinical trust in our automated predictions by generating interpretable patient clustering, patient-level clinical feature importance, and global clinical feature importance within our large real-world COVID-19 positive patient dataset. We achieved 89.38% area under receiver operating curve (AUROC) performance for severe outcomes prediction and our robust feature ranking approach identified the presence of dementia as a key indicator for worse patient outcomes. We also demonstrated that our deep-learning clustering approach outperforms traditional clustering in separating patients by severity of outcome based on mutual information performance. Finally, we developed an application for automated and fair patient risk assessment with minimal manual data entry using existing data exchange standards.

Indexed as

COVID-19HumansMachine LearningOutcome Assessment, Health CarePrognosisRetrospective StudiesRisk Assessment

Identifiers

PMID37923795
PMCPMC10624921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.